An Expanded Access Program for Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma in Japan
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Elotuzumab (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Expanded access; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 04 Jan 2017 Status changed from recruiting to completed.
- 30 Nov 2016 Planned End Date changed from 1 Apr 2017 to 1 Dec 2016.
- 30 Nov 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2016.